OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
about
Emerging Functions of RANKL in Lymphoid TissuesBiology of recently discovered cytokines: interleukin-17--a unique inflammatory cytokine with roles in bone biology and arthritisA DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cellsA novel zinc finger protein that inhibits osteoclastogenesis and the function of tumor necrosis factor receptor-associated factor 6IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in ratsc-Src control of chloride channel support for osteoclast HCl transport and bone resorptionThe molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesisHuman osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutationsThe role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models.RANK is essential for osteoclast and lymph node developmentOsteoclast differentiation factor RANKL controls development of progestin-driven mammary cancerImmunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variantsControl of RANKL gene expressionActivated human T cells express alternative mRNA transcripts encoding a secreted form of RANKLTumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligandOsteoimmunology: interactions of the bone and immune systemJun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKLA novel member of the leukocyte receptor complex regulates osteoclast differentiationGene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formationGranulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent mannerExposure to receptor-activator of NFkappaB ligand renders pre-osteoclasts resistant to IFN-gamma by inducing terminal differentiationThe role of osteoprotegerin in arthritisCollagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cellsThe present and future role of bisphosphonates in the management of patients with breast cancer.Bone loss. Factors that regulate osteoclast differentiation: an update.The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption.The molecular mechanism of osteoclastogenesis in rheumatoid arthritisRANK-RANKL signalling in cancerSignaling Pathways in Osteoclast DifferentiationRole of EMT in Metastasis and Therapy ResistanceDiametrical diseases reflect evolutionary-genetic tradeoffs: Evidence from psychiatry, neurology, rheumatology, oncology and immunologyDenosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patientsTargeting RANKL in metastasisNuclear receptors in bone physiology and diseasesRole of osteocytes in multiple myeloma bone diseaseAdvances in understanding the leukaemia microenvironmentFunctions of the osteocyte network in the regulation of bone massThe role of Snail in prostate cancerA review of denosumab for the treatment of osteoporosisOsteoimmunology: Major and Costimulatory Pathway Expression Associated with Chronic Inflammatory Induced Bone Loss
P2860
Q21131222-FCF50DB7-3C94-400F-8A04-C802D85CFF40Q21195672-46D21958-2F60-42C2-B43B-43A588594FC3Q24291798-13246A99-DE4F-47A2-821A-AF3B888228D7Q24292059-F4D6964A-B445-4556-91E8-F93A717CFC80Q24294661-3BA98B56-1EAA-4C20-AF43-785D8ED53CD2Q24296702-10EFD455-FD52-40E1-BBB4-63B2E3A1FE10Q24297505-33757DB7-9D78-4E7F-A7AB-F1D94385902AQ24310432-D94D3404-1835-447B-B746-BC527FB84BABQ24519770-11C1AEBF-468C-4F9B-86FD-DFB6C09922D8Q24598872-0EAF5C4F-3FC1-4B78-B851-E1C5A5743B06Q24605866-80DFE633-EBBF-4794-B2C3-0843EA480DD3Q24617796-47004A56-999F-4E4C-8071-92AD3C67922AQ24619669-85BD955F-0D73-4D60-BB5F-5EBFCD807399Q24632345-21D2798A-E32F-4964-823D-8BCB83E86B5DQ24653311-C849593F-254C-42C4-B4B4-7BA9AA1BEAEAQ24655113-3B4A2A92-C21F-4721-BD75-2D370B848825Q24673624-BF21A3C4-36D2-46D9-89D6-3E9C25B80AC1Q24675157-F83DAD5C-1595-45EE-9BAA-91F358F075CCQ24681552-2F69F377-D994-4A65-AE12-0ED74F8C03F5Q24683680-35665657-7740-4363-96B2-56F0753E8F5DQ24796088-FE7CE1B9-2F0E-4529-AAA7-33E6F8477DFBQ24797889-8EB71B14-5625-4C3A-B19D-B334E0D7BC2CQ24798242-B1EAC56E-F540-4931-B5F9-AD257693067BQ24802100-914325F8-84DD-4880-86BD-1E1C5645660EQ24805142-296F275B-4BA0-4629-B2A3-945BEDB87BF1Q24805207-6BF481C2-6E51-400F-9C71-B774C8561E53Q24806322-B220BEBF-9565-4703-8D69-56205F571234Q26747442-ED74502B-D5F8-49EE-BC7F-827BFC6DB305Q26766637-2775E328-B6B8-419B-93FE-7233CCAF52C2Q26772923-8653D6AE-7F49-4974-8E81-77EE84E515F8Q26782139-CAE180FA-E84A-476A-8DB4-9378D9939B5DQ26824762-B9B4AEFA-C132-414A-8261-6984AF1B7208Q26849690-232F4E08-243F-4B56-97C6-BB3EFEDFB9C8Q26853017-799704DF-8CAC-443B-AA7F-21B61DB20D3DQ26992195-F21ACBF8-0588-4CCD-B46E-BE5BFA7E94C6Q26995023-93E57023-4F14-4F18-946A-A8978D7D9B82Q27002647-E6EC203B-5603-4D04-A308-07F5E5567CF3Q27004557-090BD2D9-0181-4ADB-9C43-FA3DC32F58D5Q27005894-369B36BC-C8E6-4970-ACDD-60A8838E3B87Q27008993-3B485853-A74B-42BE-9F13-C1F601C7C5DB
P2860
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
description
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
article publié dans la revue scientifique Nature
@fr
artículu científicu espublizáu en 1999
@ast
scientific journal article
@en
vedecký článok (publikovaný 1999/01/28)
@sk
vědecký článek publikovaný v roce 1999
@cs
wetenschappelijk artikel (gepubliceerd op 1999/01/28)
@nl
наукова стаття, опублікована в січні 1999
@uk
مقالة علمية (نشرت في 28-1-1999)
@ar
name
OPGL is a key regulator of ost ...... t and lymph-node organogenesis
@ast
OPGL is a key regulator of ost ...... t and lymph-node organogenesis
@en
OPGL is a key regulator of ost ...... t and lymph-node organogenesis
@nl
type
label
OPGL is a key regulator of ost ...... t and lymph-node organogenesis
@ast
OPGL is a key regulator of ost ...... t and lymph-node organogenesis
@en
OPGL is a key regulator of ost ...... t and lymph-node organogenesis
@nl
prefLabel
OPGL is a key regulator of ost ...... t and lymph-node organogenesis
@ast
OPGL is a key regulator of ost ...... t and lymph-node organogenesis
@en
OPGL is a key regulator of ost ...... t and lymph-node organogenesis
@nl
P2093
P921
P3181
P356
P1433
P1476
OPGL is a key regulator of ost ...... t and lymph-node organogenesis
@en
P2093
A. J. Oliveira-dos-Santos
A. Wakeham
C. Capparelli
D. L. Lacey
H. Yoshida
P2888
P304
P3181
P356
10.1038/16852
P407
P577
1999-01-28T00:00:00Z
P5875
P6179
1050199905